ImmunoGen Executives

IMGNDelisted Stock  USD 18.20  0.81  4.26%   
ImmunoGen employs about 277 people. The company is managed by 14 executives with a total tenure of roughly 16 years, averaging almost 1.0 years of service per executive, having 19.79 employees per reported executive. Analysis of ImmunoGen's management performance can provide insight into the firm performance.
Mark Enyedy  CEO
President CEO, Director
Theresa Wingrove  President
Vice President - Regulatory Affairs and Quality
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

ImmunoGen Management Team Effectiveness

The company has return on total asset (ROA) of (0.0849) % which means that it has lost $0.0849 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1988) %, meaning that it created substantial loss on money invested by shareholders. ImmunoGen's management efficiency ratios could be used to measure how well ImmunoGen manages its routine affairs as well as how well it operates its assets and liabilities.

ImmunoGen Workforce Comparison

ImmunoGen is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 3,090. ImmunoGen holds roughly 277 in number of employees claiming about 9% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.26) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.23 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.23.

ImmunoGen Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ImmunoGen insiders, such as employees or executives, is commonly permitted as long as it does not rely on ImmunoGen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ImmunoGen insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

ImmunoGen Notable Stakeholders

An ImmunoGen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ImmunoGen often face trade-offs trying to please all of them. ImmunoGen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ImmunoGen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mark EnyedyPresident CEO, DirectorProfile
Theresa WingroveVice President - Regulatory Affairs and QualityProfile
Daniel JDVP OfficerProfile
Susan AltschullerVP CFOProfile
MMSc MDVP OfficerProfile
Lauren MBASenior OfficerProfile
Renee LentiniVP OfficerProfile
Stacy CoenSr OfficerProfile
Audrey BerganSenior OfficerProfile
Courtney OKonekSenior RelationsProfile
Isabel KalofonosSenior OfficerProfile
Anabel ChanHead RelationsProfile
FACP MDVP AffairsProfile
Stacy MBASenior OfficerProfile

About ImmunoGen Management Performance

The success or failure of an entity such as ImmunoGen often depends on how effective the management is. ImmunoGen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ImmunoGen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ImmunoGen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate therapies to treat cancer. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Immunogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people.

ImmunoGen Workforce Analysis

Traditionally, organizations such as ImmunoGen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ImmunoGen within its industry.

ImmunoGen Manpower Efficiency

Return on ImmunoGen Manpower

Revenue Per Employee1M
Revenue Per Executive20.5M
Net Loss Per Employee265.4K
Net Loss Per Executive5.3M
Working Capital Per Employee658K
Working Capital Per Executive13M
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Other Consideration for investing in ImmunoGen Stock

If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Commodity Directory
Find actively traded commodities issued by global exchanges
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing